New adaptation disease application of traditional Chinese medicine composition for freeing lung and vanquishing toxin
By screening the active substances in Xuanfei Baidu Granules, regulating the MAPK signaling pathway and inhibiting pulmonary fibrosis markers, Xuanfei Baidu Granules have shown significant effects in treating pulmonary fibrosis, anti-tumor, insulin resistance and hypoglycemia, solving the problem of insufficient application of traditional Chinese medicine compositions in existing technologies and expanding its clinical indications.
Patent Information
- Application Number
- CN202411082081.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-08
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-08-08
AI Technical Summary
In the treatment of respiratory diseases such as pneumonia, chronic obstructive pulmonary disease and pulmonary fibrosis, existing technologies have shown that antibiotics are not effective in inhibiting inflammation and preventing pulmonary fibrosis, and the clinical application of the traditional Chinese medicine composition Xuanfei Baidu Granules has not been fully expanded.
By screening the active substances in the blood-entering components of Xuanfei Baidu Granules, such as decaffeoyl mucoside, baicalin, luteolin and apigenin, the MAPK signaling pathway is regulated, the expression of inflammatory factors is inhibited, and combined with amygdalin to inhibit pulmonary fibrosis markers, its clinical indications are expanded to pulmonary fibrosis, anti-tumor, insulin resistance and hypoglycemia.
Xuanfei Baidu Granules significantly inhibit the expression of inflammatory factors, suppress the process of pulmonary fibrosis, exhibit anti-tumor activity, improve insulin resistance, regulate inflammatory response, and reduce blood sugar levels, thus expanding the clinical application scope of traditional Chinese medicine compositions.
Smart Images

Figure CN118903335A_ABST
Abstract
Description
Technical Field
[0001] The invention discloses a new indication and use of a traditional Chinese medicine composition for purging lungs and defeating toxicity, belonging to the field of new clinical uses of drugs. Background Art
[0002] In recent years, respiratory diseases have attracted widespread attention from all walks of life due to their high morbidity and mortality rates. Among them, pneumonia, chronic obstructive pulmonary disease and pulmonary fibrosis are more common. Its clinical symptoms mainly include cough, fever, shortness of breath, fatigue, etc. Among them, lung inflammation is a respiratory disease caused by infection with bacteria and various pathogenic microorganisms. Its abnormally active immune response can cause irreversible damage to lung tissue, and a large number of inflammatory factors produced by excessive immune response can induce excessive accumulation of extracellular matrix, thereby leading to the occurrence of pulmonary tissue fibrosis. At present, antibiotics are often used clinically to alleviate the patient's condition, but they fail to play a therapeutic role in the disease. Therefore, it is extremely important to explore Chinese medicine active substances with anti-inflammatory and anti-pulmonary fibrosis, and develop a Chinese medicine compound that can inhibit inflammation and prevent and treat pulmonary fibrosis.
[0003] The Xuanfei Baidu Chinese medicine composition of the present invention is Xuanfei Baidu granules, which is the core product of Shandong Buchang Pharmaceutical Co., Ltd., and the approval number of the medicine is: National Medicine Standard C20010003. The medicine is prepared from ephedra, gypsum, bran fried atractylodes, patchouli, artemisia annua, knotweed, verbena, coix seed, reed root, scutellaria baicalensis, boiled bitter almond, tangerine peel, and liquorice, and has the effects of purging lungs and removing dampness, clearing heat and expelling evil, and purging lungs and detoxifying. It can be used for epidemic diseases caused by dampness and toxicity in the lungs. Symptoms include fever and cough, discomfort in the pharynx, shortness of breath, fatigue, poor appetite, poor bowel movements, dark red tongue, yellow and greasy or dry fur, slippery and rapid pulse or stringy and slippery pulse, etc.
[0004] Since its launch, this product has shown significant and reliable clinical efficacy and has been well received by patients. The applicant has applied for a total of 21 patent applications for this product, namely: 202010832621.1, 202010833756.X, 202010832609.0, 202011269872.X, 202110069872.3, PCT / CN2021 / 081339, 202110431293.9, 202130306764.4, 202111334199.8, 202111368289.9, 202210032961. 5. J / 005839(630), US17914390, PCT / CN2020 / 112431, EA202292478, IAP20220476, CA3,175,596, PI2022005462, P00202210912, 202311290096.5, 2024106299082. The subjects protected by the above patent applications are: Xuanfei Baidu formula, new preparation process, new dosage form, quality inspection method, appearance packaging box, new clinical indications and other aspects. Afterwards, the applicant systematically searched and sorted out the existing technical literature related to Xuanfei Baidu, and found that the clinical diseases of the drug were mainly concentrated on: new coronavirus infection, inhibition of virus action, reduction of inflammatory response, regulation of the immune system, acute respiratory distress syndrome, treatment of severe pneumonia in the elderly, acute lung injury, Omicron virus infection and other respiratory diseases. However, during the clinical use of the drug, it was unexpectedly discovered that in addition to treating a series of lung diseases, other new therapeutic uses were also discovered, expanding the clinical treatment scope of the drug. Summary of the invention
[0005] The purpose of the present invention is to provide a new indication for the use of a traditional Chinese medicine composition for Xuanfei Baidu, specifically to provide a new clinical treatment use of a drug for treating pulmonary fibrosis, anti-tumor, insulin resistance, hypoglycemia, and natural immune regulation, to expand the scope of clinical application indications of the traditional Chinese medicine composition for Xuanfei Baidu, and to provide new medication options for clinical patients.
[0006] The technical solution of the patent application of this invention is:
[0007] Application of a Xuanfeibaidu Chinese medicine composition in the preparation of a pulmonary fibrosis medicine.
[0008] Application of a Xuanfeibaidu Chinese medicine composition in the preparation of anti-tumor drugs.
[0009] Preferably, the Chinese medicine composition can prevent and / or treat tumors by dysregulating transcription.
[0010] Preferably, the Chinese medicine composition can also be used in the preparation of insulin resistance drugs.
[0011] Preferably, the Chinese medicine composition can also be used in the preparation of blood sugar lowering drugs.
[0012] Preferably, the Chinese medicine composition can also be used in the preparation of natural immune regulation drugs.
[0013] Preferably, the Chinese medicine composition can also be used in the preparation of drugs for regulating or inhibiting inflammatory responses.
[0014] The beneficial effects of the Xuanfeibaidu Chinese medicine composition of the present invention are:
[0015] ⑴. In order to verify the use of the Xuanfei Baidu Chinese medicine composition in the treatment of pulmonary fibrosis, the applicant used LPS to stimulate Raw264.7 cells to construct an in vitro inflammatory model, screened the chemical substances that may have anti-inflammatory activity in the blood components of Xuanfei Baidu Granules by the Griess method, and then used the expression levels of IL-6 and TNF-α proteins in the cell supernatant as indicators to verify the high-throughput screening results, and then used TGF-β1 to stimulate MRC5 cells to establish an in vitro pulmonary fibrosis model, and used the expression level of FN protein as a screening condition. The high-content screening method based on immunofluorescence was used to explore the biologically active components in the blood components that prevent and treat pulmonary fibrosis, and the Western Blot experiment was used to verify the results of the high-content screening.
[0016] This experimental study found that decaffeoyl verbascoside, baicalin, luteolin and apigenin are active substances with anti-inflammatory effects in the blood components of Xuanfei Baidu Granules, among which baicalin and luteolin can exert anti-inflammatory effects by regulating the phosphorylation levels of ERK protein and JNK protein in the MAPK signaling pathway. In addition, experimental verification found that amygdalin is an active substance with anti-pulmonary fibrosis effect in the blood components of Xuanfei Baidu Granules, which can inhibit the expression of FN protein and α-SMA protein to achieve the purpose of preventing and treating pulmonary fibrosis. The present invention describes the active substances with anti-inflammatory and anti-pulmonary fibrosis in the blood components of Xuanfei Baidu Granules and the anti-inflammatory action pathway, thereby confirming that the Xuanfei Baidu Chinese medicine composition of the present invention has the effect of treating pulmonary fibrosis.
[0017] (2) The inhibitory effect of the Xuanfei Baidu Chinese medicine composition on tumor cells HCT-116 and PC3 is positively correlated with the increase of concentration. The Xuanfei Baidu Chinese medicine composition of the present invention has a relatively good inhibitory effect on tumor cells HCT-116. At a concentration of 150 μg mL -1 When the inhibitory rates of the Xuanfei Baidu Chinese medicine composition on HCT-116 and PC3 were 68.84% and 51.30% respectively, the above experimental data further illustrate that the Xuanfei Baidu Chinese medicine composition of the present invention has certain anti-tumor activity.
[0018] ⑶. The Xuanfei Baidu Chinese medicine composition of the present invention can significantly promote the glucose uptake function of insulin-resistant HepG-2 cells, and is dose-dependent. The results of the efficacy experiment found that the Xuanfei Baidu Chinese medicine composition of the present invention can reduce the glucose content in the supernatant of HepG-2 cells, inhibit gluconeogenesis, and further regulate and improve insulin resistance to achieve the goal of lowering blood sugar levels.
[0019] ⑷. Experimental results: The present invention found that Xuanfei Baidu Granule and component A, medicinal materials Polygonum cuspidatum, Verbena, Apricot Kernel, Licorice, Atractylodes macrocephala, Patchouli, Lemongrass, monomers Hesperidin, Apigenin, and Isoliquiritigenin can inhibit LPS-induced NFκB_luc activation; Xuanfei Baidu component C, D, and monomers Formononetin, Naringenin, Physaceae methyl ether-1-glucoside, and Physaceae can further promote LPS-induced NFκB activation. The above screening results are all potential active substances for regulating inflammatory responses.
[0020] The present invention found that Xuanfei Baidu Granule, medicinal materials verbena, licorice, patchouli, monomers quinic acid, catechins can inhibit LPS-induced AP1_luc activation; Xuanfei Baidu components C, D, and monomers isoliquiritigenin, formononetin, licorice chalcone B and other 8 monomers can further promote LPS-induced AP1 activation. The above screening results are all potential active substances for regulating inflammatory responses.
[0021] The present invention finds that Xuanfei Baidu Granule and component A, medicinal materials Polygonum cuspidatum, Verbena officinalis, Apricot kernel, Licorice, Atractylodes macrocephala, Patchouli, Semen Lepidii, monomers isoliquiritigenin, Licorice chalcone B, isoliquiritigenin, Licorice chalcone C can inhibit LPS-induced ISRE_luc activation; monomers apigenin-7-O-glucuronide and formononetin can further promote LPS-induced ISRE activation. The above screening results are all potential active substances for regulating inflammatory responses.
[0022] In order to more fully understand the implementation of the present invention, the present invention is further described below through typical examples. The following and pharmacodynamics are used to prove the beneficial therapeutic effect of the Xuanfei Baidu Chinese medicine composition. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] The drawings described herein are used to provide a further understanding of the present invention and constitute a part of the present invention. The illustrative embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation of the present invention. The Xuanfei Baidu Chinese medicine composition described in the present invention is Xuanfei Baidu granules.
[0024] Figure 1 -The compound inhibits the expression of inflammatory factors IL-6 and TNF-α;
[0025] Figure 2- The regulation of decaffeoyl verbascoside on the phosphorylation expression of ERK protein and JNK protein;
[0026] Figure 3 --The regulation of baicalin on the phosphorylation expression of ERK protein and JNK protein;
[0027] Figure 4 -Regulation of luteolin on the phosphorylation expression of ERK protein and JNK protein;
[0028] Figure 5 -Apigenin regulates the phosphorylation expression of ERK protein and JNK protein;
[0029] Figure 6 -High-content screening of anti-pulmonary fibrosis active substances in blood components;
[0030] Figure 7 -The regulation of anti-pulmonary fibrosis active substances on the expression of α-SMA protein and COL1A1 protein; among them, 1 is ephedrine; 6-quercetin-3-O-β-D-glucose-7-O-β-D-gentiobioside; 11-amygdalin; 17-apiosyl glycyrrhizin. DETAILED DESCRIPTION
[0031] In order to better understand the present invention, several experimental examples are listed below to illustrate its new use in the pharmaceutical field. The following experiments are intended to illustrate the present invention rather than to limit the present invention.
[0032] Example 1 Pharmacological experiment of Xuanfeibaidu against fibrosis of the present invention
[0033] 1.1 Experimental methods and materials
[0034] 1.1.1 Experimental instruments
[0035] Table 1 Experimental instruments
[0036]
[0037]
[0038] 1.1.2 Experimental reagents and materials
[0039] Table 2 Experimental reagents and materials
[0040]
[0041]
[0042] 1.1.3 Related compound information
[0043] Table 3 Compound information
[0044]
[0045]
[0046] 1.1.4 Griess method for high-throughput screening of anti-inflammatory substances
[0047] The experiment was conducted using cells in the logarithmic growth phase. 10 μL of the prepared cell suspension was aspirated and mixed with 10 μL of trypan blue dye. The density of the cell suspension was then calculated using a cell counter. The cell density was diluted to 5×105 cells per milliliter using complete culture medium. The diluted cell suspension was inoculated into a 96-well plate at a volume of 100 μL per well and incubated overnight in an incubator. After the cells adhered to the wall, the group experiment was started, with three replicate wells set up for each group:
[0048] (1) Normal group: After the cells adhered, the original culture medium was replaced with serum-free basal medium and the cells were cultured normally. After 24 hours, the culture medium was replaced with serum-free medium for further culture.
[0049] (2) Modeling group: After the cells adhered to the wall, the original culture medium was replaced with serum-free DMEM for normal culture; after 24 h of culture, the culture medium was replaced with serum-free culture medium containing 1 mg / mL LPS modeling agent;
[0050] (3) Drug group: After the cells adhered to the wall, the cells were given serum-free medium containing drug solution to pre-treat the cells; 24 hours later, the original drug-containing medium was removed and serum-free drug-containing medium containing 1 mg / mL LPS modeling agent was added. After the modeling agent and drug were incubated together for 24 hours, 50 μL of the cell supernatant of each group was taken into a new 96-well plate, protected from light, and 50 μL of Griess Reagent I and 50 μL of Griess Reagent II were added to each well in sequence. The absorbance value was detected at 540 nm.
[0051] 1.1.5 High-content screening of anti-pulmonary fibrosis active substances
[0052] After cell digestion and centrifugation, the supernatant was discarded, fresh cell complete medium was added, and the cell clusters were gently blown to disperse. The cells were seeded in a 96-well plate and placed in a cell culture incubator for overnight incubation. After the cells adhered to the wall, the cell culture medium was replaced with a high-glucose medium containing 1% serum and placed in an incubator for 24 hours. The cells were divided into a normal group, a modeling group, a positive drug group, and a drug administration group. Two replicate wells were set up in each group. 10ng / mL of TGF-β1 modeling agent was added to the modeling group to construct a pulmonary fibrosis model; the positive drug group was pretreated with 2μM SB431542 for 24 hours, the culture medium was discarded, and 10ng / mL TGF-β1 modeling agent and 2μM SB431542 solution were added; the drug administration group was pretreated with the compound for 24 hours, the drug-containing culture medium was aspirated, and the cells were given 10ng / mL of TGF-β1 modeling agent and compound at the same time. The compound administration concentration was the maximum non-toxic dose.
[0053] After 48 h of incubation, the next step of the experiment was carried out.
[0054] (1) Washing: Remove the cell culture plate, remove the original cell culture medium, and add PBS to wash three times, with an interval of 5 minutes each time, to wash away the residual culture medium and dead cells in the well plate;
[0055] (2) Fixation: Add 50 μL of 4% paraformaldehyde to each well and fix at room temperature for 30 min. Pour off the 4% paraformaldehyde and wash three times with PBS, with an interval of 5 min between each wash.
[0056] (3) Permeabilization: Add 50 μL of 0.5% TritonX-100 permeabilization agent to each well, incubate at room temperature for 15 min, pour out the 0.5% TritonX-100 permeabilization agent, and wash three times with PBS, with an interval of 5 min each time;
[0057] (4) Blocking: Add 50 μL of 5% BSA blocking solution to each well and block for 1 h at room temperature. Pour away the 5% BSA blocking solution and wash three times with PBS, with an interval of 5 min between each wash.
[0058] (5) Antibody incubation: Add 40 μL of FN protein primary antibody (dilution ratio of 1:400) to each well, incubate in a 4°C refrigerator overnight, and recover the antibody; wash three times with PBS, each time with an interval of 5 min; add 40 μL of FITC-labeled fluorescent secondary antibody (dilution ratio of 1:200) to each well, incubate at room temperature for 1 h, recover the antibody, and wash three times with PBS, each time with an interval of 5 min;
[0059] (6) Nuclear staining and photography: 40 μL Hochest stain solution (dilution ratio of 1:1000) was added to each well and incubated at room temperature for 15 min. The Hochest stain solution was discarded and the cells were washed three times with PBS, each time with an interval of 5 min. After washing, the cell culture plate was placed in the Image Xpress Micro Confocal high-content imaging analysis system for cell imaging. The shooting magnification was set to 20×, and 10 images were collected from each well for statistical analysis. The same exposure time and shooting position were maintained during the image collection process.
[0060] 1.1.6 Western Blot Detection
[0061] According to the prediction results of network pharmacology, Xuanfei Baidu Granules and its active substances may play an anti-inflammatory role through the MAPK signaling pathway. This prediction result is now experimentally verified.
[0062] Myocardial tissue was lysed with RIPA protein lysis buffer (containing protease inhibitors, phosphatase inhibitors and PMSF), and the supernatant was aspirated after homogenate centrifugation as the total tissue protein. The protein concentration was determined using the BCA Protein Assay Kit, and the Loading buffer was added to heat denature the protein. The SDS-PAGE gel was separated by electrophoresis, and the protein blot was transferred to a PVDF membrane and blocked with 5% blocking solution. After blocking, the PVDF membrane was placed in the primary antibody (1:1000) diluted with the primary antibody diluent and incubated at 4°C overnight. The PVDF membrane was placed in the secondary antibody (1:5000) and incubated at room temperature for 1 hour. The Bio-rad chemiluminescence imager and ECL colorimetric solution were used to develop and acquire images, and the data were analyzed using Image Lab software.
[0063] The relevant information of antibodies involved in this experiment is shown in Table 4 below:
[0064] Table 4 Related information of MAPK pathway protein antibodies
[0065]
[0066]
[0067] 2.1 Experimental Results
[0068] High-throughput screening of active substances in the blood-entering components of Xuanfei Baidu Granules that exert anti-inflammatory effects
[0069] An in vitro inflammatory model was constructed by LPS-induced Raw264.7 cells, and the Griess method was used to evaluate whether the compounds with clear sources in the blood components may have anti-inflammatory effects. After 24 hours of LPS stimulation of Raw264.7 cells, the NO secretion in the cell supernatant was significantly increased compared with the normal group. The NO release in the drug-treated group was less than 75% of the NO release in the LPS group as the screening condition for positive results. The screening results showed that at the maximum non-toxic dose, the NO release rates of decaffeoyl verbascoside (4), baicalin (20), luteolin (37), apigenin (40), nomilin (45) and patchouli ketone (48) were all less than 75% of the LPS group. Therefore, it was inferred that the above six compounds can inhibit the release of NO stimulated by LPS and may have certain anti-inflammatory activity.
[0070] 2.2 ELISA method to verify the anti-inflammatory active substances in blood components
[0071] According to the results of network pharmacology enrichment, IL-6 and TNF-α may be the main targets of anti-inflammatory active substances entering the blood to inhibit inflammatory response. Therefore, IL-6 and TNF-α were used as indicators to verify the anti-inflammatory effects of the six compounds, namely, decaffeoyl verbascoside, baicalin, luteolin, apigenin, nomiline and patchouli ketone.
[0072] As the instruction manual Figure 1 As shown in the figure, compared with the normal group, after LPS stimulation of Raw264.7 cells, the expression of IL-6 and TNF-α in the cell supernatant of the model group was significantly increased, while decaffeoyl verbascoside, scutellarin, luteolin, and apigenin effectively reduced the LPS-induced IL-6 expression in the cell supernatant, and scutellarin and luteolin could also reduce the LPS-induced TNF-α expression in the cell supernatant. In summary, it can be determined that decaffeoyl verbascoside, scutellarin, luteolin, and apigenin are compounds with anti-inflammatory activity in the blood-entering components of Xuanfei Baidu Granules.
[0073] 2.3 Anti-inflammatory active substances regulate the expression of proteins related to the MAPK signaling pathway
[0074] The MAPK signaling pathway can participate in human immune regulation by regulating various cell activities such as cell growth, differentiation and apoptosis. JNK protein and ERK protein are the main components of its signaling pathway. The MAPK signaling pathway is a key pathway for regulating inflammatory response. Inhibiting the expression of MAPK pathway-related proteins is helpful for the treatment of inflammatory diseases. Combined with the results of network pharmacology enrichment, it is speculated that decaffeoyl verbascoside, baicalin, luteolin and apigenin can inhibit inflammation by inhibiting the phosphorylation level of MAPK pathway-related proteins.
[0075] This experiment discusses and analyzes whether the anti-inflammatory active substances in the blood components of Xuanfei Baidu Granule can exert anti-inflammatory effects by inhibiting the phosphorylation levels of ERK protein and JNK protein. Figure 2-5 As shown in the results, decaffeoyl verbascoside can inhibit the expression of LPS-induced ERK protein phosphorylation, but the inhibitory effect is poor, and it cannot regulate the phosphorylation level of JNK protein. Baicalin and luteolin can simultaneously inhibit the expression of LPS-induced ERK protein and JNK protein phosphorylation. And compared with decaffeoyl verbascoside, the inhibitory effect on ERK protein phosphorylation is more significant. Apigenin failed to reduce the phosphorylation levels of JNK protein and ERK protein. Therefore, it is concluded that baicalin and luteolin in the blood-entering components of Xuanfei Baidu Granule can significantly inhibit the expression of ERK protein and JNK protein phosphorylation in the MAPK signaling pathway, thereby exerting an anti-inflammatory effect.
[0076] 2.4 Results of high-content screening of anti-pulmonary fibrosis active substances in the blood components of Xuanfei Baidu
[0077] As a growth factor, TGF-β1 can activate fibroblasts, accumulate extracellular matrix, induce fibrosis, and thus upregulate the expression of α-SMA, FN, and COL1A1 proteins. In this experiment, TGF-β1 was used to stimulate MRC5 cells to establish an in vitro pulmonary fibrosis model, and the active substances that can resist pulmonary fibrosis in the blood components of Xuanfei Baidu Granules were screened and confirmed by high-content screening and Western Blot experiments.
[0078] Results Instructions Attached Figure 6 As shown in the figure, compared with the normal group, the TGF-β1 group significantly increased the expression of FN protein, and the expression of FN protein decreased after the administration of the positive drug SB431542, so it was judged that the model may be successfully established. The TGF-β1 group was normalized, and the average fluorescence intensity of FN protein in the drug administration group was less than 55% of the average fluorescence intensity of FN protein in the TGF-β1 group as the screening condition for positive results. According to the high content screening results, ephedrine, quercetin-3-O-β-D-glucose-7-O-β-D-gentiobioside, amygdalin and apigenin liquiritin effectively reduced the high expression of FN protein induced by TGF-β1 and inhibited the transformation process of myofibrosis. Therefore, the above four compounds may be the active substances against pulmonary fibrosis in the blood-entering components of Xuanfei Baidu Granules.
[0079] 2.5 Verification of anti-pulmonary fibrosis activity
[0080] According to the results of immunofluorescence high-throughput screening, ephedrine, quercetin-3-O-β-D-glucose-7-O-β-D-gentiobioside, amygdalin and apigenin glycyrrhizin may be the active substances in the blood-entering components of Xuanfei Baidu Granules that have the ability to prevent and treat pulmonary fibrosis. Since there is a certain probability of false positives in the high-throughput screening results, it is necessary to further verify the results of high-throughput screening through Western Blot experiments. The experimental results are as follows Figure 3-7 As shown in the figure, compared with the normal group, the expression of α-SMA protein and COL1A1 protein was significantly upregulated after TGF-β1 stimulation of cells, and the expression of α-SMA and COL1A1 was significantly reduced after intervention with the positive drug SB431542, which is consistent with the immunofluorescence results. Figure 7 It can be seen that the above four compounds failed to reduce the expression of COL1A1, but quercetin-3-O-β-D-glucose-7-O-β-D-gentiobioside, amygdalin and apigenin liquiritin could inhibit the expression of α-SMA induced by TGF-β1 to varying degrees, and the inhibitory effect of amygdalin was the most significant. Therefore, it can be judged that amygdalin can achieve the purpose of preventing and treating pulmonary fibrosis by inhibiting the expression of α-SMA protein and FN protein and delaying the transformation of myofibroblasts. It is an active substance with anti-pulmonary fibrosis in the blood-entering components of Xuanfei Baidu Granules.
[0081] First, an in vitro inflammatory model was established by stimulating Raw264.7 cells with LPS, and the release of NO in the cell supernatant was used as an indicator. The NO release in the drug group was less than 75% of the NO release in the model group as a screening condition to screen the anti-inflammatory active substances in the blood components of Xuanfei Baidu Granules. It was found that decaffeoyl verbascoside, baicalin, luteolin, apigenin, nomilin and patchouli ketone effectively inhibited the release of NO in the cell supernatant, and may be compounds with anti-inflammatory activity in the blood components. Then, the expression of two inflammatory factors, TNF-α and IL-6, in the cell supernatant was detected by ELISA method to further verify the anti-inflammatory efficacy of the above six compounds. According to the experimental results, decaffeoyl verbascoside, baicalin, luteolin and apigenin inhibited the release of inflammatory factor IL-6, while baicalin and luteolin reduced the expression of TNF-α protein. Therefore, it can be concluded that decaffeoyl verbascoside, baicalin, luteolin and apigenin are compounds with anti-inflammatory activity among the blood-entering components of Xuanfei Baidu Granules.
[0082] According to the results of network pharmacology analysis, Xuanfei Baidu Granules and its active substances may exert anti-inflammatory effects through the MAPK signaling pathway. The network pharmacology prediction results were further verified by Western Blot experiments. It was found that decaffeoyl verbascoside had an inhibitory effect on the phosphorylation expression of ERK protein, but the inhibitory effect was poor. Baicalin and luteolin could significantly inhibit the phosphorylation levels of ERK protein and JNK protein, but apigenin failed to regulate the phosphorylation of ERK protein and JNK protein. Therefore, its anti-inflammatory mechanism needs to be further studied. Secondly, an in vitro pulmonary fibrosis model was established using TGF-β1-induced MRC5 cells, and the active substances in the blood components of Xuanfei Baidu Granules that can prevent and treat pulmonary fibrosis were discussed. According to the experimental results, the positive drug SB431542 effectively inhibited the high expression of FN protein, α-SMA protein and COL1A1 protein induced by TGF-β1, indicating that the model was successfully constructed. The immunofluorescence method was used to perform high-throughput screening of active substances with anti-pulmonary fibrosis in the blood components of Xuanfei Baidu Granules. The average fluorescence intensity of FN protein was used as an indicator. Compared with the TGF-β1 group, it was found that ephedrine, quercetin-3-O-β-D-glucose-7-O-β-D-gentiobioside, amygdalin and apigenin liquiritin effectively reduced the expression of FN protein. Therefore, the above four compounds may have anti-pulmonary fibrosis effects. The results of the high-throughput screening experiment were then verified by Western Blot experiments, and it was found that amygdalin significantly inhibited the expression of α-SMA protein and was an active substance with anti-pulmonary fibrosis in the blood components.
[0083] In summary, this experimental study found that decaffeoyl verbascoside, baicalin, luteolin and apigenin are active substances with anti-inflammatory effects in the blood components of Xuanfei Baidu Granules, among which baicalin and luteolin can exert anti-inflammatory effects by regulating the phosphorylation levels of ERK protein and JNK protein in the MAPK signaling pathway. In addition, experimental verification found that amygdalin is an active substance with anti-pulmonary fibrosis effect in the blood components of Xuanfei Baidu Granules, which can inhibit the expression of FN protein and α-SMA protein to achieve the purpose of preventing and treating pulmonary fibrosis. The present invention describes the active substances with anti-inflammatory and anti-pulmonary fibrosis in the blood components of Xuanfei Baidu Granules and the anti-inflammatory action pathway.
[0084] Example 2: Experimental study on the anti-tumor activity of the Xuanfeibaidu Chinese medicine composition of the present invention
[0085] Referring to the CCK8 method for detecting cell activity, the proliferation inhibition effect of the Xuanfei Baidu Chinese medicine composition on HCT-116 tumor cells and PC3 tumor cells was studied. Tumor cells in the logarithmic growth phase were adjusted to a cell density of 5.0×10 4The cells were inoculated into 96-well plates, with 6 replicate wells for each experimental condition. They were incubated in an incubator for 24 hours. -1 , 150 μg·mL -1 , 200 μg·mL -1 ), add to each well, culture for 24h; aspirate the culture medium of each well, add 100μL of PBS solution containing 10% CCK-8, continue to culture for 2 hours, and measure the absorbance value at the detection wavelength of 450nm. Calculate the inhibition rate of Xuanfei Baidu sample on each cell according to the following formula.
[0086] Calculation formula: Cell proliferation inhibition rate % = A control group - A experimental group / A control group - A blank group
[0087] ×100%.
[0088] Experimental results: The inhibitory effect of the Xuanfei Baidu Chinese medicine composition on tumor cells HCT-116 and PC3 is positively correlated with the increase of concentration. The Xuanfei Baidu Chinese medicine composition of the present invention has a relatively good inhibitory effect on tumor cells HCT-116. At a concentration of 150 μg·mL -1 When the inhibitory rates of the Xuanfei Baidu Chinese medicine composition on HCT-116 and PC3 were 68.84% and 51.30% respectively, the above experimental data further illustrate that the Xuanfei Baidu Chinese medicine composition of the present invention has certain anti-tumor activity.
[0089] Example 3: Effect of improving insulin resistance in HepG-2 cells
[0090] 3.1 Effect of the Xuanfei Baidu Chinese medicine composition of the present invention on the viability of HepG-2 cells
[0091] The effects of different concentrations of Xuanfei Baidu Chinese medicine composition on the viability of HepG-2 cells were investigated, and 30, 50, 100, and 150 μM mL -1 The concentration is the experimental concentration.
[0092] 3.2 Effect of the Xuanfei Baidu Chinese medicine composition of the present invention on glucose uptake in insulin-resistant HepG-2 cells
[0093] The effect of the Xuanfei Baidu Chinese medicine composition of the present invention on glucose uptake in insulin-resistant HepG-2 cells can be seen as follows: compared with the blank group, the change in glucose content in the supernatant was measured by using a glucose detection kit. At the same time, compared with the model control group, the Xuanfei Baidu group (30-150 μM·mL -1) showed different degrees of glucose content reduction in the supernatant, which also shows that the Xuanfei Baidu Chinese medicine composition of the present invention can significantly promote the glucose uptake function of insulin-resistant HepG-2 cells, and is dose-dependent. Through the measurement and fitting, it can be seen that the concentration range of EC50 of the Xuanfei Baidu group of the present invention is about 19.73 to 38.16. It can be seen that the Xuanfei Baidu Chinese medicine composition of the present invention can reduce the glucose content in the supernatant of HepG-2 cells, inhibit gluconeogenesis, and further regulate and improve insulin resistance to achieve the goal of lowering blood sugar levels.
[0094] Example 4: Pharmacological activity test of the Xuanfeibaidu Chinese medicine composition of the present invention
[0095] 4.1 Experimental methods and materials
[0096] Take cells in the logarithmic growth phase, digest and count the adherent cells, and then inoculate them into 6-well plates. Culture overnight until the cell confluence is appropriate for transfection. According to the MOI (multiplicity of infection) calculation formula (MOI = virus liquid volume (mL) × virus titer (TU / mL) / total number of cells), add the corresponding volume of virus liquid according to the virus titer of the lentivirus liquid and place it in the incubator for transfection for 24 hours. Then, discard the supernatant, add fresh complete culture medium, and place it in a 37°C, 5% CO2 incubator for culture.
[0097] The suspended cells were counted and inoculated into 24-well plates for direct transfection. According to the MOI calculation formula, the corresponding volume of virus solution was added according to the virus titer of the lentivirus solution, and the culture plate was sealed and centrifuged at 1000×g for 1 hour at room temperature. After centrifugation, the supernatant was discarded, and the cells were resuspended with 1mL of fresh complete medium and placed in a 37°C, 5% CO2 incubator for culture.
[0098] 1 to 3 days after transfection, puromycin was added to select cells that stably expressed the reporter gene. After the expression rate reached more than 90%, the cells were seeded into a 96-well white plate. After a certain period of administration, the Bright-Lumi reporter gene detection reagent was added, and the cell plate was placed in an ELISA instrument to detect the luciferase chemiluminescence value.
[0099] THP1_NFκB / AP1 / ISRE_luc reporter gene model: The stably transfected THP1 cells selected by puromycin were centrifuged and counted, then inoculated into a 96-well all-white plate. They were induced to differentiate into adherent M0 macrophages with 100 ng / mL PMA, and then treated with stimulants such as PAM3CSK4 and LPS. Bright-Lumi reporter gene detection reagent was added at the detection time point, and the cell plate was placed in a microplate reader to detect the luciferase chemiluminescence value.
[0100] All models are evaluated based on the Z' factor to determine whether they can be used for high-throughput screening: Z' = 1-(3×(σp+σn) / |(μp–μn)|)(positive control standard deviation: negative control standard deviation; positive control mean; negative control mean).
[0101] 4.2 Screening of active substances in traditional Chinese medicine
[0102] XFBD-related substances: XFBD granules, XFBD major components A to E, 13 extracts of XFBD formula herbs, and 63 monomers, a total of 82 substances have been made into drug plates. Set 1 replicate well for each concentration, 3 times. Set 1 replicate well for each substance, 2 to 3 times. Dexamethasone is used as the positive drug of this model.
[0103] Experimental process: Use the reporter gene model to perform high-throughput screening of the transcription factor activation and regulation effects of the test drug. Pre-protect with traditional Chinese medicine for 24 hours, and then stimulate with the stimulator for 6 hours before detecting the expression of the reporter gene.
[0104] 4.3 Validation of the efficacy of active ingredients
[0105] Cell model: Thp1 cells were counted and inoculated into 12-well plates, and PMA was added to induce cell differentiation and adhesion. After pre-protection, the cells were stimulated with 500 ng / mL of the new coronavirus S2 protein or LPS for 24 hours to construct a Thp1 cell inflammation model. Chinese medicine components to be evaluated: SXG-41 and SXG-59, Xuanfei Baidu Granules, Xuanfei Baidu Large Components C and D, Licorice Extract, 40 (Isoliquiritigenin), 42 (Licorice Chalcone B), 47 (Naringenin), 54 (Glycyrrhizic Acid), 59 (Glycyrrhizin). All were pre-protected for 24 hours. Detection indicators: Fluorescence quantitative PCR (qPCR), detecting the mRNA expression of genes such as IL-6 and CCL-2. ELISA detected the secretion of IL-6, TNF-α and IFN-β in THP1 cells.
[0106] 4.4 Statistical methods
[0107] GraphPad Prism 8 was used for statistical analysis, and all data were calculated as mean ± standard deviation. One-way ANOVA was used to compare multiple samples, and P < 0.05 was considered statistically significant.
[0108] 4.5 Experimental Results
[0109] 4.5.1 Construction of multiple reporter gene model
[0110] Evaluation of modeling effect of THP1_NFκB_luc reporter gene model
[0111] The model was stimulated with TNF-α, PAM3CSK4 (PAM), LPS and Poly (I: C) + PAM3CSK4 (P2P), and the inhibitory effects of NFκB inhibitor parthenolide (PTL), TLR2 inhibitor C29, AP-1 inhibitor SR11302 (SR) and JAK2 / STAT3 inhibitor protosedinoside A (PTA) on the expression and activation of NFκB_luc reporter gene were evaluated. The results show that the reporter gene model can respond to the stimulation of multiple stimulants, and the expression of NFκB reporter gene is increased through the activation of multiple natural immune signaling pathways, and its activation level can be inhibited by multiple inhibitors. According to the calculation results of Z' factor, see Table 2, LPS500ng / mL was finally determined for subsequent high-throughput screening.
[0112] 4.5.2 Evaluation of modeling effect of THP1_AP1_luc reporter gene model
[0113] The model was stimulated with TNF-α, PAM3CSK4, LPS and P2P, and the inhibitory effects of PTL, C29, SR11302 and PTA on the activation of AP1_luc reporter gene expression were evaluated. The results show that the reporter gene model can respond to the stimulation of multiple stimulants, and the expression of AP1 reporter gene is increased through the activation of multiple natural immune signaling pathways, and its activation level can be inhibited by multiple inhibitors. According to the calculation results of the Z' factor (see Table 2), LPS 500ng / mL was finally determined for subsequent high-throughput screening.
[0114] 4.5.3 Evaluation of modeling effect of THP1_ISRE_luc reporter gene model:
[0115] The model was stimulated with IFN-β, PAM3CSK4, LPS and P2P, and the inhibitory effects of PTL, C29, SR11302 and PTA on the expression and activation of the ISRE_luc reporter gene were evaluated. The results show that the reporter gene model can respond to the stimulation of multiple stimulants, and the expression of the ISRE reporter gene is increased through the activation of multiple natural immune signaling pathways, and its activation level can be inhibited by multiple inhibitors. According to the calculation results of the Z' factor, LPS 500ng / mL was finally determined for subsequent high-throughput screening.
[0116] Table 5 Calculation of Z' factor for multiple reporter gene model
[0117]
[0118] 4.5.4 Screening of natural immunomodulatory active substances based on NFκB-Luc reporter gene
[0119] A total of 5 components, 13 medicinal materials and 63 monomers of Xuanfei Baidu Granule were screened, and it was found that Xuanfei Baidu Granule and component A, medicinal materials Polygonum cuspidatum, Verbena officinalis, Apricot kernel, Licorice, Atractylodes macrocephala, Patchouli, Semen Lepidii, and monomers hesperidin, apigenin, and isoliquiritigenin could inhibit LPS-induced NFκB_luc activation; Xuanfei Baidu component C and D, as well as monomers formononetin, naringenin, physaccharin methyl ether-1-glucoside, and physaccharin could further promote LPS-induced NFκB activation. The above screening results are all potential active substances for regulating inflammatory response.
[0120] 4.5.5 Screening of natural immunomodulatory active substances based on AP1-Luc reporter gene
[0121] The present invention screened a total of 82 Xuanfei Baidu related substances, and found that Xuanfei Baidu granules, medicinal materials verbena, licorice, patchouli, monomers quinic acid, catechins can inhibit LPS-induced AP1_luc activation; Xuanfei Baidu components C, D, and monomers isoliquiritigenin, formononetin, licorice chalcone B and other 8 monomers can further promote LPS-induced AP1 activation. The above screening results are all potential active substances for regulating inflammatory responses.
[0122] 4.5.6 Screening of anti-inflammatory active substances based on ISRE-Luc reporter gene
[0123] A total of 82 Xuanfei Baidu related substances were screened, and it was found that Xuanfei Baidu granules and component A, medicinal materials Polygonum cuspidatum, Verbena officinalis, Apricot kernel, Licorice, Atractylodes macrocephala, Patchouli, Semen Lepidopterae, monomers isoliquiritigenin, Licorice chalcone B, isoliquiritigenin, and Licorice chalcone C can inhibit LPS-induced ISRE_luc activation; monomers apigenin-7-O-glucuronide and formononetin can further promote LPS-induced ISRE activation. The above screening results are all potential active substances for regulating inflammatory responses.
[0124] The experimental results showed that the THP1_NFκB_luc, THP1_AP1_luc and THP1_ISRE_luc reporter gene models targeting monocytes and macrophages were successfully constructed. The entity library covering 82 substances including Xuanfei Baidu Granules-components-herbal extracts-monomers was screened using the triple reporter gene system, and the anti-inflammatory and anti-interferon effects of Xuanfei Baidu Granules and components, as well as the pro-inflammatory and anti-interferon effects of isoliquiritigenin were further confirmed in the LPS-stimulated THP1 cell natural immune response activation model.
Claims
1. Use of a Xuanfei Baidu Chinese medicine composition in the preparation of pulmonary fibrosis drugs.
2. Use of a Xuanfei Baidu Chinese medicine composition in the preparation of anti-tumor drugs.
3. The use according to claim 2, It is characterized in that The Chinese medicinal composition can prevent and / or treat tumors through transcriptional dysregulation.
4. The use according to any one of claims 1 to 3, It is characterized in that The traditional Chinese medicine composition can also be used in the preparation of insulin resistance drugs.
5. The use according to claim 4, It is characterized in that The Chinese medicine composition can also be used in the preparation of blood sugar lowering drugs.
6. The use according to claim 1, It is characterized in that The Chinese medicine composition can also be used in the preparation of natural immune regulation drugs.
7. The use according to claim 1, It is characterized in that The Chinese medicine composition can also be used in the preparation of drugs for regulating or inhibiting inflammatory reactions.
Citation Information
Patent Citations
Traditional chinese medicine for dispersing lung qi and detoxicating
CA3175596A1
Anti-coronavirus traditional Chinese medicine composition as well as preparation method and application thereof
CN111789918A
Anti-coronavirus traditional Chinese medicine granules and preparation method and application thereof
CN111888434A
Anti-coronavirus traditional Chinese medicine composition and use thereof in treatment of inflammation
CN111888435A
Traditional Chinese medicine for ventilating lung and relieving toxin
CN112245543A
